Research
Bifidobacterium bifidum
37 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Are Bifidobacterium Species Key Players in the Progression of Type 1 Diabetes? A Systematic Review.
Systematic review investigating the association of Bifidobacterium with Type 1 Diabetes (T1D) across different disease stages. The review included 25 studies with 4533 individuals, highlighting variability in Bifidobacterium abundance in T1D, with higher abundance in at-risk asymptomatic individuals and lower abundance in those with established T1D.
A Systematic Review on Effect of Bifidobacterium Isolated from Skin Microbiota on GLP-1 Production to Alleviate Human Ailments.
Systematic review of 267 papers on the effects of Bifidobacterium isolated from skin microbiota on GLP-1 production. Bifidobacterium shows potential in modulating skin health, metabolic functions, and enhancing glucose tolerance and insulin sensitivity, indicating therapeutic potential for diabetes management and skin aging prevention.
Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial.
This randomized, quadruple-blind, placebo-controlled trial assessed the effect of a multispecies probiotic on antibiotic-associated diarrhea (AAD) in children. The probiotic did not reduce the risk of AAD but did reduce the overall risk of diarrhea during and after antibiotic treatment.
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
This multicentre, randomised, double-blind, placebo-controlled clinical trial assessed the efficacy of heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in treating irritable bowel syndrome (IBS). The primary endpoint of at least 30% improvement in abdominal pain and adequate relief of IBS symptoms was achieved by 34% of patients in the treatment group compared to 19% in the placebo group, indicating a significant positive effect on gut health.
Bifidobacterium bifidum TMC3115 ameliorates milk protein allergy in by affecting gut microbiota: A randomized double-blind control trial.
RCT of 256 infants with cow's milk protein allergy comparing Bifidobacterium bifidum TMC3115 to placebo over 6 months. B. bifidum TMC3115 reduced allergic scores, improved anti-inflammatory responses, and altered gut microbiota composition, suggesting benefits for gut health and immunity.
School-Age Neurodevelopmental and Atopy Outcomes in Extremely Preterm Infants: Follow-Up from the Single Versus Triple-Strain Bifidobacterium Randomized Controlled Trial.
Follow-up study of extremely preterm infants from the SiMPro trial comparing single-strain versus triple-strain Bifidobacterium probiotic supplementation. Neurodevelopmental, growth, and atopy-related outcomes at school age were comparable between groups, indicating both formulations were safe.
Preventive effects of combined live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus cereus tablets on radiation pneumonitis-associated with cyberknife treatment for pulmonary malignancies.
RCT investigating the preventive effects of combined live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus cereus tablets on radiation pneumonitis in patients undergoing CyberKnife treatment for pulmonary malignancies. The experimental group showed significantly lower incidence of radiation pneumonitis, delayed onset, and improved quality of life compared to the control group.
Effects ofBB536 andMCC1274 on Body Composition in Normal and Overweight Adults in Randomized Placebo-Controlled Study.
RCT of 100 adults with BMI between 23 and 30, comparing probiotics BB536 and MCC1274 to placebo over 16 weeks. The probiotics group showed significant reductions in abdominal visceral fat area, total abdominal fat area, and serum triglyceride levels, with suppressed BMI increase compared to placebo.
The Effects of Bifidobacterium Probiotic Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis of Animal Models and Clinical Evidence.
Systematic review and meta-analysis of animal studies and human RCTs assessing Bifidobacterium probiotic supplementation on blood glucose markers. BF supplementation showed no effect on fasting blood glucose in human RCTs but reduced FBG concentrations in animal models of obesity, MetS, or T2D. The study highlights translational gaps and suggests BF may be more effective in conditions of hyperglycemia.
Safety and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-blind, placebo-controlled trial.
A multi-centre randomized, double-blind, placebo-controlled trial evaluated the safety and tolerance of three probiotic strains (Bifidobacterium longum subsp. infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052) in 221 healthy infants aged 3 to 12 months. The study found that growth metrics and adverse events were equivalent across all groups, indicating that these probiotics are safe and well tolerated in infancy.
Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress: a secondary analysis of a randomised trial.
Secondary analysis of a randomized, double-blind, placebo-controlled study with 581 undergraduate students. Bifidobacterium bifidum R0071 decreased stress-associated diarrhoea-related symptoms and self-reported stress scores during a stressful period, compared to placebo.
Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study.
RCT of 581 academically stressed undergraduate students comparing the effects of Bifidobacterium bifidum, Bifidobacterium longum ssp. infantis, and Lactobacillus helveticus on cold/flu symptoms. B. bifidum resulted in a greater proportion of healthy days and a lower percentage of participants reporting a day of cold/flu compared to placebo.
Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study.
Double-blind, randomized, placebo-controlled trial of 100 healthy Japanese adults consuming Bifidobacterium bifidum YIT 10347-fermented milk or placebo for 4 weeks. The YIT10347 group showed significant relief in gastrointestinal symptoms such as postprandial discomfort and epigastric pain compared to placebo.
Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics.
RCT in obese humans comparing the effects of prebiotic galactooligosaccharides (GOS) and probiotic strains Bifidobacterium adolescentis IVS-1 and Bifidobacterium lactis BB-12, alone or as synbiotics. IVS-1 increased total bifidobacteria and improved colonic permeability, as did GOS, but no synergistic effects were observed with synbiotics.
A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
A multicenter, randomized, double-blind, placebo-controlled, crossover trial assessed the efficacy of a probiotic mixture of Bifidobacterium infantis M-63, breve M-16V, and longum BB536 in children with IBS and FD. The probiotic mixture significantly improved abdominal pain resolution and quality of life in children with IBS, but not in those with FD.
Consumption of a Bifidobacterium bifidum Strain for 4 Weeks Modulates Dominant Intestinal Bacterial Taxa and Fecal Butyrate in Healthy Adults.
RCT assessing the impact of Bifidobacterium bifidum strain Bb on the intestinal microbial ecosystem of healthy adults. The probiotic intake modulated the relative abundance of dominant taxa in the fecal microbiota and fecal butyrate levels, indicating potential effects on gut health.
Probiotics and growth in preterm infants: A randomized controlled trial, PREMAPRO study.
RCT of 199 preterm infants comparing daily supplementation with probiotics (Bifidobacterium lactis and Bifidobacterium longum) to placebo over 4-6 weeks. No significant differences in postnatal growth or body composition were observed between the groups. Probiotic administration was safe with no adverse effects.
Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota.
Open trial of bifidobacterial supplementation to 130 pregnant women and their infants, compared to 36 control pairs, to assess allergy prevention. The probiotic group showed a significantly reduced risk of developing eczema/atopic dermatitis in infants and altered fecal microbiota composition.
Effect of Bifidobacterium bifidum containing yoghurt on dental plaque bacteria in children.
Double-blind, randomized crossover study with 52 children to assess the effect of Bifidobacterium bifidum DN-173 010 in yogurt on dental plaque bacteria. No significant effect on dental plaque mutans streptococci levels was observed.
Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.
RCT of 122 IBS patients comparing Bifidobacterium bifidum MIMBb75 to placebo for 4 weeks. MIMBb75 significantly reduced IBS symptoms and improved quality of life, with 57% responder rate compared to 21% in placebo group.
Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial.
RCT investigating the effect of a probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) on preventing eczema in infants at high risk of allergy. The prevalence of eczema at 1 year was significantly lower in the probiotic group compared to placebo, indicating a positive preventive effect.
Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans.
RCT evaluating the effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori infection and gastric health in humans. The BF-1 group showed lower H. pylori urease activity and improved gastric mucosal conditions compared to placebo, indicating potential benefits for gut health.
Bifidobacterium bifidum TMC3115 Can Characteristically Influence Glucose and Lipid Profile and Intestinal Microbiota in the Middle-Aged and Elderly.
RCT of Bifidobacterium bifidum TMC3115 in 47 middle-aged and elderly subjects with mild hyperglycaemia and dyslipidaemia. TMC3115 significantly decreased plasma total cholesterol and LDL-C levels, improved defaecation frequency and faecal odour, and modulated intestinal microbiota composition.
The mixture of bifidobacterium associated with fructo-oligosaccharides reduces the damage of the ocular surface.
Pilot RCT evaluating the effects of a mixture of Bifidobacterium lactis and Bifidobacterium bifido with fructo-oligosaccharides on tear film in dry eye syndrome. Group treated with the symbiotic showed significant improvements in Schirmer test scores and reduced bacterial growth compared to control.
Health benefits of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults.
The study conducted a preliminary open trial and a double-blind, placebo-controlled, crossover trial to examine the effects of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults. The trials showed that ingestion of the probiotic significantly decreased gastric and lower abdominal symptoms, with no side effects reported.
Effect of Bifidobacterium administration on very-low-birthweight infants.
This study evaluated the efficacy and safety of early administration of Bifidobacterium bifidum OLB6378 in very-low-birthweight infants. The early administration group showed higher daily bodyweight gain and reached feeding volume milestones faster than the later administration group, without increasing morbidity.
Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria.
A randomized, double-blind, controlled feeding trial with 18 elderly volunteers tested a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and an inulin-based prebiotic. The synbiotic increased fecal bifidobacterial populations and diversity, indicating improved gut health.
Reduction of rotavirus infection in children receiving bifidobacteria-supplemented formula.
RCT conducted at Pakkred Babies Home, Bangkok, Thailand, with 175 children aged 6-36 months. The study tested the effect of bifidobacteria-supplemented milk-based formula on rotavirus infection. Children receiving the supplemented formula showed no significant change in rotavirus antibody titres, suggesting protection against symptomatic rotavirus infection.
Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus.
Double-blind, placebo-controlled trial of infants aged 5-24 months receiving standard infant formula or formula supplemented with Bifidobacterium bifidum and Streptococcus thermophilus. The supplemented group showed reduced incidence of acute diarrhoea and rotavirus shedding compared to the control group.
Efficacy of probiotics (Bifidobacterium bifidum G9-1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open-label, single-arm study (BIRDIE study).
This multicenter, open-label, single-arm study evaluated the efficacy of Bifidobacterium bifidum G9-1 in 30 patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation. The study found significant improvements in stool form, defecation frequency, and quality of life without worsening glycemic control and renal function.
Bifidobacterium improves oestrogen-deficiency-induced osteoporosis in mice by modulating intestinal immunity.
Animal study using an ovariectomized mouse model to investigate the effects of Bifidobacterium on osteoporosis. Bifidobacterium treatment improved bone mineral density, bone volume/total volume ratio, and trabecular number, and suppressed bone loss by modulating intestinal immunity and reducing gut inflammation.
Effects of probiotic Bifidobacterium bifidum G9-1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open-label, single-arm, exploratory research trial.
Open-label, single-arm exploratory study of 40 type 2 diabetes mellitus patients treated with metformin, given probiotic Bifidobacterium bifidum G9-1 for 10 weeks. Significant improvements were observed in gastrointestinal symptoms, including diarrhea and constipation, without changes in glycated hemoglobin levels.
Anti-inflammatory Bifidobacterium strains prevent dextran sodium sulfate induced colitis and associated gut microbial dysbiosis in mice
The study screened Bifidobacterium strains for their anti-inflammatory effects and evaluated their efficacy against dextran sodium sulfate induced colitis in mice. Three strains, B. longum Bif10, B. breve Bif11, and B. longum Bif16, showed protective effects against colitis, reducing inflammatory markers and improving gut microbial composition.
Relationship between intestinal colonization of Bifidobacterium bifidum in infants and the presence of exogenous and endogenous growth-promoting factors in their stools.
The study investigated the relationship between intestinal colonization of Bifidobacterium bifidum in infants and the presence of growth-promoting factors in their stools or diet. Thirty-one infants were inoculated with B. bifidum, and its colonization was monitored. The study found no significant relationship between B. bifidum colonization and the amounts of growth-promoting factors in stools, although these factors were higher in human milk-fed infants.
Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes.
RCT in 25 elderly individuals comparing lyophilized Bifidobacterium bifidum and Lactobacillus acidophilus to placebo over 28 days. The treatment significantly reduced colonic inflammatory infiltration and increased B cell frequency in peripheral blood, suggesting modulation of immunological and inflammatory response.
Bifidobacterium modulation of tumor immunotherapy and its mechanism
This review focuses on the immunomodulatory effects of Bifidobacteria in malignancies and explores the possible mechanisms of action of Bifidobacteria on immunotherapy. It aims to provide a basis for further research and better application of Bifidobacteria in clinical practice.
The probiotic Bifidobacterium in the management of Coronavirus: A theoretical basis
The paper discusses the theoretical basis for using Bifidobacterium probiotics in managing COVID-19. It suggests that Bifidobacterium may ameliorate the cytokine storm associated with COVID-19 by modulating immune responses and potentially enhancing vaccine efficacy.